Page last updated: 2024-10-25

cilostazol and Osteoporosis, Postmenopausal

cilostazol has been researched along with Osteoporosis, Postmenopausal in 1 studies

Osteoporosis, Postmenopausal: Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.

Research Excerpts

ExcerptRelevanceReference
"Cilostazol has been reported to alleviate the metabolic syndrome induced by increased intracellular adenosine 3',5'-cyclic monophosphate (cAMP) levels, which is also associated with osteoclast (OC) differentiation."1.42Cilostazol attenuates ovariectomy-induced bone loss by inhibiting osteoclastogenesis. ( Choi, HS; Chung, HT; Joe, Y; Ke, K; Safder, AM; Suh, JH; Sul, OJ, 2015)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ke, K1
Safder, AM1
Sul, OJ1
Suh, JH1
Joe, Y1
Chung, HT1
Choi, HS1

Other Studies

1 other study available for cilostazol and Osteoporosis, Postmenopausal

ArticleYear
Cilostazol attenuates ovariectomy-induced bone loss by inhibiting osteoclastogenesis.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Animals; Bone Density; Cell Differentiation; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Ki

2015